NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
- State
- Under way
- Phase
- Phase 2
- People
- 75 planned
- Started
- 26 Nov 2020
- Primary completion
- 30 Jun 2027
- Arms
- Treatment (oleclumab, durvalumab)
- Results
- None posted
- 26 Nov 2020: Trial started
- 16 Dec 2020: Trial registered